REG - ReNeuron Group plc - Block Listing Review and Total Voting Rights

ReNeuronAnnouncement

28/02/2019 07:05

RNS Number : 3492R
ReNeuron Group plc
28 February 2019
 


 



28 February 2019


AIM: RENE



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Block Listing Review and Total Voting Rights
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
 



Name:


ReNeuron Group plc




Name of Scheme:


ReNeuron Share Option Schemes




Period of Return:


From 1 September 2018 to 28 February 2019




Balance of unallotted securities under scheme(s) from previous return:


902,825 Ordinary Shares (of 1p each)
 




Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):


N/A




Less: Number of securities issued/allotted under scheme(s) during period


 
N/A




Equals: Balance under scheme(s) not yet issued/allotted at end of period:


902,825 Ordinary Shares




Number and class of securities originally admitted and the date of admission:


20,000 ordinary shares on 13 May 2010



 
 
Total Voting Rights
The Company has 31,646,186 Ordinary Shares in issue, all with voting rights. The Company holds no Ordinary Shares in treasury.  The figure of 31,646,186 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
 
ENDS
 
ENQUIRIES:
 



ReNeuron


+44 (0)20 3819 8400




Olav Hellebø , Chief Executive Officer








Michael Hunt, Chief Financial Officer








Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham








Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)








Nplus1 Singer Advisory LLP


+44 (0) 20 7496 3000




Mark Taylor (Joint Broker)







 
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  
 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   
 
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKODBCBKDFBB